Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

The wrong track
When reporters asked former Railway Minister Lalu Prasad for a reaction on why his successor Mamata Banerjee was trying to mock his work by bringing out her White Paper, he asked, “Do you know any tantric? I need to consult one.” As the reporters wondered why the RJD chief needed a tantric, Prasad added, “I think there is something wrong with the time of my birth. Earlier, I faced this fodder scam and now people are after me for unnecessary reasons.

Dr Reddy's plans to launch Lipitor's generic version in US
Drug maker Dr Reddy’s Laboratories plans to launch generic version of the world’s largest selling anti-cholesterol medicine ‘Lipitor’ in the US market in the next 2-3 years.

News of the day

Food inflation to ease next month: Montek
The Planning Commission today said food inflation will come down next month from a more than a decade"s high of around 20 per cent, as apprehensions about adverse effect of drought were easing.
Corporate

Ranbaxy gets nod to sell Ran-Simvastatin tablets in Canada

Ranbaxy Laboratories, received the final approval in Canada to manufacture and market Ran-Simvastatin tablets from Health Canada, Therapeutic Products Directorate. The total generic market size of Simvastatin tablets in Canada is $CAD153 million. - Zandu Pharma Q1 profit doubles at Rs 11.12 cr - Ranbaxy gets Canada"s nod to mkt anti-hypertension drug - Teva Pharma recalls anti-anxiety drug Propofol - Shasun to invest Rs 100 cr for setting up new Vizag plant - Ranbaxy recalls skin disease drugs from US - Pharma, healthcare industry disappointed with Budget Ranbaxy has got the approval for Ran-Simvastatin in 5, 10, 20 and 40 mg strengths, through its wholly-owned subsidiary Ranbaxy Pharmaceuticals- Canada Inc (RPCI), Gurgaon-based (RPCI) said in a statement. “We look forward to marketing this organically developed product in all strengths that will be commercialised at an affordable price. Ran-Simvastatin represents the second approval granted to RPCI in July,” said Paul Drake, President RPCI. On Monday, the Pharmaceutical firm had received approval from the Canadian drug regulator TPD to market and manufacture "Ran-Amlodipine tablets", used in treating hypertensions.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009